TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ).
IRLAB Therapeutics AB has announced a significant advancement in its development of the drug candidate IRL757, aimed at treating apathy in Parkinson’s disease. In partnership with the McQuade Center for Strategic Research and Development, LLC (MSRD), IRLAB has secured a $4 million investment to progress IRL757 into a Phase Ib clinical study. This study will assess the drug’s safety, tolerability, and potential efficacy in patients with Parkinson’s disease who experience apathy. The move is based on promising preclinical and Phase I study results, highlighting IRL757’s unique mechanism in reversing nerve signaling disruptions associated with apathy. This development positions IRLAB as a potential leader in addressing a significant unmet need in the treatment of apathy, impacting millions globally.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a pharmaceutical company focused on discovering and developing novel treatments for Parkinson’s disease. The company is particularly involved in addressing neurological conditions, with a market focus on providing solutions for unmet medical needs such as apathy, a common symptom in Parkinson’s and other neurodegenerative diseases.
Average Trading Volume: 202,371
Technical Sentiment Signal: Sell
Current Market Cap: SEK248M
See more data about IRLAB.A stock on TipRanks’ Stock Analysis page.